Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
  • Sign in
    My account
    Logout
AI 90-DAY FORECAST
BULLISH SIGNAL DETECTED · Alpha
██.█% Sign up free to reveal

Allogene Therapeutics, Inc. (ALLO) AI Forecast

Our AI ranks Allogene Therapeutics, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.

✓ Free account • ✓ 30-day free trial

$ALLO Bullish Signal Full forecast available
Sign Up Free

Allogene Therapeutics, Inc. (ALLO) Stock Forecast Sept. 21, 2026

Allogene Therapeutics, Inc. (ALLO) AI Stock Price Forecast & Investment Analysis

Allogene Therapeutics, Inc. Stock Price Chart and Technical Analysis

Loading chart...

Allogene Therapeutics, Inc. (ALLO) - Comprehensive Stock Analysis & Investment Research

Deep dive into Allogene Therapeutics, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on September 21, 2026 (UTC)

Allogene Therapeutics, Inc. Investment Summary

When evaluating whether Allogene Therapeutics, Inc. (ALLO) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Allogene Therapeutics, Inc. (ALLO) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry. . With a market capitalization of $584 million, the company is a small-cap stock that may offer higher growth potential but also carries higher volatility.

Financial Performance Analysis

Our comprehensive financial analysis covers Allogene Therapeutics, Inc.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Allogene Therapeutics, Inc. along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Allogene Therapeutics, Inc. is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Allogene Therapeutics, Inc.

Sign Up Free
Corporate Identity

Allogene Therapeutics, Inc. (Stock Symbol: ALLO) is a prominent company operating within the Life Sciences sector, with a specific focus on the Biological Products, (No Diagnostic Substances) industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Allogene Therapeutics, Inc.'s leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Allogene Therapeutics, Inc....

Sector & Industry Analysis

In-depth sector dynamics and industry context for Allogene Therapeutics, Inc....

Unlock Full Company Profile

Get complete details about Allogene Therapeutics, Inc.

Sign Up Free
Revenue & Growth Analysis
Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Allogene Therapeutics, Inc....

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Allogene Therapeutics, Inc....

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Allogene Therapeutics, Inc....

Unlock Financial Analysis

Get complete financial metrics for Allogene Therapeutics, Inc.

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Allogene Therapeutics, Inc.'s AI Price Forecast

Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

4537 Stocks in the out-of-sample test
73.7% Rebalance periods with a positive net return
Daily Updates
Start 30-Day Free Trial →

✓ 30-day free trial • ✓ Cancel anytime

Strategic Market Position

Allogene Therapeutics, Inc. strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace. As a small-cap company, it represents an emerging market participant with potentially significant growth opportunities. Small-caps often offer greater growth potential as they capture market share and scale their operations, though this comes with higher risk and volatility. Success at this stage can lead to substantial returns for early investors who identify winning business models.

Industry Competitive Landscape

Allogene Therapeutics, Inc. competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency

The company currently shows negative free cash flow of $-103 million . Negative free cash flow may reflect heavy investment in growth, working capital needs, or operational challenges. This is common for high-growth companies investing aggressively but warrants attention for mature businesses.

Financial Strength & Leverage

Current ratio of 10.72 demonstrates strong short-term liquidity with current assets significantly exceeding current liabilities. This provides a substantial buffer for meeting near-term obligations and handling unexpected financial needs.

Allogene Therapeutics, Inc. (ALLO) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Allogene Therapeutics, Inc. stock analysis.

Deep dive into Allogene Therapeutics, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Allogene Therapeutics, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Allogene Therapeutics, Inc.:

P/B Ratio 1.34x
Market Cap $584M
EPS $-0.77
Book Value/Share $1.26
FCF/Share $-0.30
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Allogene Therapeutics, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Allogene Therapeutics, Inc.: An ROE of -37.9% indicates room for improvement in shareholder value creation.

ROE -37.9%
ROA -30.1%
ROIC -34.8%
Operating Margin -3886.1%
Net Margin -3566.7%
EBT Margin -3489.0%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Allogene Therapeutics, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Allogene Therapeutics, Inc.: A current ratio of 10.72 indicates strong liquidity.

Current Ratio 10.72x
D/E Ratio 0.26x
Financial Leverage 1.26x
Interest Coverage -6.6x
Working Capital $308M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Allogene Therapeutics, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Allogene Therapeutics, Inc.: Free cash flow of $-103M indicates cash challenges that need attention.

Operating Cash Flow -$102M
Free Cash Flow -$103M
Capital Spending -$400K
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Allogene Therapeutics, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Allogene Therapeutics, Inc.:

Understanding Financial Statement Data

What these metrics mean: Key figures from Allogene Therapeutics, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Allogene Therapeutics, Inc.:

Income Statement
Operating Income -$180M
Net Income -$165M
R&D Expense $123M
Balance Sheet Highlights (USD millions)
Total Current Assets $340M (61.9% of assets)
Cash & Short-term Investments $39M (7.0% of assets)
Total Liabilities $114M (20.7% of assets)
Short-term Debt $26M (4.7% of assets)
Dividend & Shareholder Information
Shares Outstanding 345M

Latest Allogene Therapeutics, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Allogene Therapeutics, Inc. (ALLO) stock price and investment outlook.

📰 Loading...

Where ALLO sits on the market map

Explore the map →

Allogene Therapeutics, Inc. Industry Peers - Biological Products, (No Diagnostic Substances)

Companies classified under the same SEC industry code as Allogene Therapeutics, Inc. (Biological Products, (No Diagnostic Substances)): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.

Company Ticker Symbol 90-Day AI Forecast (Alpha) Market Cap (USD M) P/E Ratio P/B Ratio
ALLO ██% $584M x 1.3x
AMGN ██% $212.55B 24.3x 18.2x
GILD ██% $186.13B x 15.7x
MRNA ██% $61.50B x 9.1x
ARGX ██% $61.15B x x
RVMD ██% $40.93B x 15.7x
BIIB ██% $32.34B 23.6x 1.7x
BNTX ██% $24.78B x x
MESO ██% $19.62B x x
NBIX ██% $14.86B 21.1x 4.0x
EXEL ██% $14.18B x 7.7x
HALO ██% $12.76B 30.9x 88.9x
TECH ██% $11.35B 62.4x 5.4x
TWST ██% $10.47B x 23.5x
APGE ██% $10.22B x x
RGEN ██% $9.98B 240.3x 4.7x
KRYS ██% $9.97B 41.3x 7.3x
KYMR ██% $9.79B x 6.5x
QGEN ██% $9.40B x 2.5x
IBRX ██% $8.99B x x
PCVX ██% $8.65B x 3.1x
IMVT ██% $7.63B x 10.4x
CGON ██% $6.94B x 6.7x
SRRK ██% $5.68B x 22.4x
CRSP ██% $5.64B x 3.2x
IOVA ██% $4.64B x 6.3x
ADPT ██% $4.45B x 31.1x
RLAY ██% $4.13B x 4.6x
DBVT ██% $3.58B x 21.2x
TARS ██% $3.43B x 9.9x
DNLI ██% $3.27B x 3.9x
BEAM ██% $2.61B x 2.4x
BCRX ██% $2.24B x x
SCNI ██% $2.16B x 275.4x
ADMA ██% $2.13B 12.6x 5.2x
KOD ██% $2.06B x 33.7x
RXRX ██% $2.05B x 2.2x
VCEL ██% $2.05B 84.6x 5.5x
ALVO ██% $1.83B x x
VIR ██% $1.79B x 1.8x
COAG ██% $1.77B x 3.9x
NVAX ██% $1.67B x x
IMCR ██% $1.65B x 3.9x
TSHA ██% $1.64B x 4.2x
CGEM ██% $1.37B x 4.3x
MGTX ██% $1.27B 16.1x 5.9x
VOR ██% $1.27B x x
MAZE ██% $1.25B x 2.8x
REPL ██% $1.23B x 11.7x
JATT ██% $1.17B x 6.0x
ODTX ██% $1.17B x 2.8x
IMTX ██% $1.16B x x
VALN ██% $1.14B x x
GLUE ██% $1.03B x 2.1x
SLDB ██% $955M x 2.6x
SANA ██% $928M x 6.0x
CADL ██% $858M x 6.8x
FDMT ██% $841M x 2.1x
AURA ██% $660M x 2.1x
PRME ██% $566M x 14.2x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Allogene Therapeutics, Inc. Stock Forecast

How accurate are Allogene Therapeutics, Inc. stock predictions?

A per-ticker accuracy statistic for ALLO is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

What factors influence Allogene Therapeutics, Inc. stock price forecasts?

Our analysis considers Allogene Therapeutics, Inc.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Allogene Therapeutics, Inc. a good investment in 2026?

Based on our AI analysis, Allogene Therapeutics, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Allogene Therapeutics, Inc. forecasts updated?

Allogene Therapeutics, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on September 21, 2026.

Want a simpler view of Allogene Therapeutics, Inc.?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...